Who Paid My Doc
Erin Bohula
Cardiovascular Disease Boston, MA Medical Doctor
NPI 1619176732 CMS profile 1092617
75 Francis St, Boston, MA 02115
General payments
$374,840
Research payments
$45,843
Ownership & investment interest
$0
Research they led as principal investigator
$9,638,929
Through program year 2025, Erin Bohula of Boston, MA is reported in the CMS Open Payments database as having received $374,840 across 134 general payments and $45,843 in research payments paid to them. Separately, studies naming them as principal investigator received $9,638,929 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $58,743 | 21 | |
| 2024 | General | $63,864 | 19 | |
| 2023 | General | $45,649 | 9 | |
| 2023 | Research | $45,843 | 9 | |
| 2022 | General | $47,420 | 10 | |
| 2021 | General | $12,750 | 3 | |
| 2020 | General | $39,777 | 15 | |
| 2019 | General | $106,638 | 57 |
Beside peers
- Erin Bohula
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Erin Bohula were reported at $58,743. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Erin Bohula | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $106,638 | $450 | $127–$1,392 | $163 |
| 2020 | $39,777 | $242 | $77–$751 | $114 |
| 2021 | $12,750 | $335 | $101–$1,037 | $132 |
| 2022 | $47,420 | $395 | $121–$1,211 | $149 |
| 2023 | $45,649 | $443 | $136–$1,283 | $160 |
| 2024 | $63,864 | $450 | $136–$1,323 | $164 |
| 2025 | $58,743 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 8 billing codesPaid by Medicare
$32,768
Medicare patients
576
Services billed
859
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 60% | |
| Atrial fibrillation | 54% | |
| Heart failure | 52% | |
| Arthritis | 52% | |
| Chronic kidney disease | 46% | |
| Diabetes | 43% | |
| Depression | 43% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Repatha |
|
$158 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
143 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Massachusetts
Marc Sabatine
Cardiovascular Disease · Boston, MA
Elizabeth Nabel
Cardiovascular Disease · Boston, MA
Kenneth Rosenfield
Cardiovascular Disease · Boston, MA
Kevin Croce
Cardiovascular Disease · Chestnut Hill, MA
James Januzzi
Cardiovascular Disease · Boston, MA
Muthiah Vaduganathan
Cardiovascular Disease · Boston, MA
Related records
Cardiovascular Disease in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.